Novan (NOVN) – Globe Newswire
-
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Trea
-
Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis
-
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
-
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
-
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
-
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
-
Novan Focuses Strategic Direction and Announces Restructuring
-
Sandoz Canada improves patients’ access to treatment with the launch of three new generics
-
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
-
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
-
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
-
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
-
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
-
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Novan to Report Full Year 2022 Financial Results on March 30, 2023
-
Novan to Report Full Year 2022 Financial Results on March 30, 2023
-
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
-
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
-
Novan Announces Closing of $6.0 Million Registered Direct Offering
-
Novan Announces Closing of $6.0 Million Registered Direct Offering
-
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Novan Announces $6.0 Million Registered Direct Offering
-
Novan Announces $6.0 Million Registered Direct Offering
-
Novan Moves Forward with Unified Corporate Branding
-
Novan Moves Forward with Unified Corporate Branding
-
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
-
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
-
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
-
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
-
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
-
Sandoz Canada Launches PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin
-
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
-
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
-
Sandoz Canada supports Ontario policy change to cover biosimilars which will generate significant cost savings and improve patient access to quality medicines
-
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
-
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
-
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
-
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
-
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
-
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
-
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
-
Sandoz Canada launches PrSandoz® Apremilast
-
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
-
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
Back to NOVN Stock Lookup
